Until now, GM-CSF has been routinely used in clinic to treat neutropenia for repopulating myeloid cells in post-chemo/radiotherapy cancer patients or post-bone marrow transplantation patients [14]. The gene discussed is CSF2; the disease is Decreased total neutrophil count.